Vinpocetine Forte Canon vial 10 mg – [30 tablets]

Description

Vinpocetine Forte Kanon Pharmacodynamics
Improves brain metabolism by increasing glucose and oxygen uptake by brain tissue.
Increases resistance of neurons to hypoxia, enhances glucose transport to the brain through the blood-brain barrier, and shifts glucose breakdown to a more energy-saving aerobic route; selectively blocks Ca2+-dependent phosphodiesterase; increases levels of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP) and adenosine triphosphate (ATP) in the brain.
Enhances the metabolism of brain noradrenaline and serotonin; has an antioxidant effect.
Reduces platelet aggregation and increased blood viscosity; increases erythrocyte elasticity and blocks erythrocyte utilization of adenosine; helps increase erythrocyte oxygen output.
Increases cerebral blood flow; reduces cerebral vascular resistance without significant changes in systemic blood flow. Does not have the effect of “stealing” and increases blood supply, especially in ischemic areas of the brain.

Indications
Neurology: as symptomatic treatment in the aftermath of ischemic stroke, vascular dementia; vascular vertebrobasilar insufficiency, atherosclerosis of cerebral vessels, hypertensive and posttraumatic encephalopathy.
Ophthalmology: chronic vascular diseases of the vasculature and retina.
Otology: hearing loss of the perceptual type, Meniere’s disease, tinnitus.

Contraindications
– Hypersensitivity to vinpocetine and other components of the drug;
– The acute phase of a hemorrhagic stroke;
– Severe form of coronary heart disease;
– Severe cardiac rhythm disturbances;
– pregnancy, breastfeeding;
– children under 18 years of age (due to lack of clinical trial data);
– Lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Pregnancy and lactation:
Vinpocetine penetrates the placental barrier and is therefore contraindicated for use in pregnancy. The concentration of vinpocetine in the placenta and in the blood of the fetus is lower than in the blood of the pregnant woman. At high doses, placental bleeding and spontaneous abortions are possible, probably as a result of increased placental blood supply.
Within one hour after vinpocetine intake, 0.25% of the drug dose enters the breast milk. Breast feeding should be discontinued during the use of the drug.

Dosage and administration method

• Orally, after meal, the standard daily dose is 10 mg 2-3 times a day.
• The maximum daily dose is 30 mg. The therapeutic effect occurs approximately one week after starting to take the drug.
• The course of treatment is determined by the doctor (1-3 months). Repeated courses 2-3 times a year are possible. Before cancelling the drug the dose should be gradually reduced.
• There is no need to reduce the dose in case of kidney and/or liver diseases.